Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Recurrence 3Colorectal Neoplasms 3Sezary Syndrome 2Rectal Neoplasms 2Ovarian Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Colonic Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Lymphoma, T-Cell 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma 1Lung Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 58Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 25Irinotecan 24Carboplatin 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × Folic Acid × Clear all
NCT00034463 2006-07-19

ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡